U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07928193) titled 'Sac-TMT in Salivary Gland Cancers' on Oct. 27.
Brief Summary: This is a Phase 2, open-label, non-randomized, parallel, two-cohort study evaluating the efficacy and safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) monotherapy in patients with advanced, recurrent, or metastatic salivary gland carcinomas who have received no more than 3 prior non-curative systemic treatment regimens. The study evaluates the activity of Sac-TMT separately in two independent cohorts based on tumor histology: Cohort 1 for Adenoid Cystic Carcinoma (ACC) and Cohort 2 for Non-Adenoid Cystic Carcinoma (non-ACC).
Study Start Date: March, 2027
Study Type:...